

Nã°ria GuaÃ±abens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5795559/publications.pdf>

Version: 2024-02-01

80
papers

3,646
citations

117625

34
h-index

133252

59
g-index

87
all docs

87
docs citations

87
times ranked

3204
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i> , 2017, 105, 11-17. | 2.9 | 373 |
| 2 | Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 503-511. | 2.8 | 291 |
| 3 | Mutations in the gene encoding the latency-associated peptide of TGF- β 1 cause Camurati-Engelmann disease. <i>Nature Genetics</i> , 2000, 26, 273-275. | 21.4 | 205 |
| 4 | Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 573-577. | 3.7 | 163 |
| 5 | Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281. | 3.6 | 132 |
| 6 | Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2010, 138, 2348-2356. | 1.3 | 115 |
| 7 | Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 458-465. | 2.8 | 113 |
| 8 | Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 579-604. | 2.8 | 102 |
| 9 | Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2268-2274. | 0.4 | 96 |
| 10 | The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 3-21. | 2.8 | 83 |
| 11 | Collagen-Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 731-738. | 2.8 | 82 |
| 12 | Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2013, 58, 2070-2078. | 7.3 | 81 |
| 13 | Osteoporosis in chronic liver disease. <i>Liver International</i> , 2018, 38, 776-785. | 3.9 | 79 |
| 14 | Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy. <i>Archives of Internal Medicine</i> , 2003, 163, 789. | 3.8 | 74 |
| 15 | Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. <i>Arthritis and Rheumatism</i> , 1997, 40, 461-468. | 6.7 | 70 |
| 16 | Sodium fluoride prevents bone loss in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1992, 15, 345-349. | 3.7 | 67 |
| 17 | 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. <i>Bone</i> , 2012, 51, 54-58. | 2.9 | 67 |
| 18 | Collagen type β 1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. <i>Hepatology</i> , 2001, 33, 554-560. | 7.3 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Calcific Periarthritis as the Only Clinical Manifestation of Hypophosphatasia in Middle-Aged Sisters. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 929-934. | 2.8 | 64 |
| 20 | Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment. <i>Clinics in Liver Disease</i> , 2008, 12, 407-424. | 2.1 | 61 |
| 21 | Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. <i>Hepatology</i> , 2011, 54, 2104-2113. | 7.3 | 61 |
| 22 | Liver and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 84-94. | 3.0 | 58 |
| 23 | The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis. <i>Current Osteoporosis Reports</i> , 2014, 12, 90-97. | 3.6 | 57 |
| 24 | Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1682-1699. | 3.6 | 53 |
| 25 | Osteomalacia revisited. <i>Clinical Rheumatology</i> , 2011, 30, 639-645. | 2.2 | 52 |
| 26 | Treatment of bone disorders in liver disease. <i>Journal of Hepatology</i> , 2006, 45, 445-453. | 3.7 | 48 |
| 27 | Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. <i>Transplant International</i> , 2009, 22, 198-206. | 1.6 | 47 |
| 28 | Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580. | 1.9 | 47 |
| 29 | Management of osteoporosis in liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 438-445. | 1.5 | 44 |
| 30 | Clinical Guidelines on Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2327-2329. | 2.8 | 43 |
| 31 | Non-Isomerized C-Telopeptide Fragments Are Highly Sensitive Markers for Monitoring Disease Activity and Treatment Efficacy in Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 588-595. | 2.8 | 42 |
| 32 | Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 311-315. | 1.6 | 38 |
| 33 | Prevalence of Paget's disease of bone in Spain. <i>Bone</i> , 2008, 43, 1006-1009. | 2.9 | 38 |
| 34 | Search for hidden secondary causes in postmenopausal women with osteoporosis. <i>Menopause</i> , 2010, 17, 135-139. | 2.0 | 37 |
| 35 | Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 24-28. | 3.7 | 36 |
| 36 | Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1935-1944. | 2.8 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1014-1021. | 2.8 | 29 |
| 38 | Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. <i>Liver International</i> , 2007, 27, 492-497. | 3.9 | 27 |
| 39 | Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. <i>Liver International</i> , 2013, 33, 1029-1038. | 3.9 | 27 |
| 40 | Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1725-1733. | 2.8 | 27 |
| 41 | Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1206-1214. | 3.4 | 26 |
| 42 | Reference intervals for bone turnover markers in Spanish premenopausal women. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 293-303. | 2.3 | 26 |
| 43 | Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 23, 266-269. | 2.7 | 23 |
| 44 | Incidence of Mutations in the <i>ALPL</i>, <i>GGPS1</i>, and <i>CYP1A1</i> Genes in Patients With Atypical Femoral Fractures. <i>JBMR Plus</i> , 2019, 3, 29-36. | 2.7 | 23 |
| 45 | The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. <i>Endocrine</i> , 2019, 64, 441-455. | 2.3 | 22 |
| 46 | Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 197-203. | 3.4 | 21 |
| 47 | High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 347-354. | 2.7 | 19 |
| 48 | Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?. <i>Calcified Tissue International</i> , 2013, 93, 571-576. | 3.1 | 19 |
| 49 | Displasia fibrosa. Revisi3n clĂnica y abordaje terapĂ©utico. <i>Medicina ClĂnica</i> , 2016, 147, 547-553. | 0.6 | 19 |
| 50 | Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. <i>Gene</i> , 2020, 725, 144167. | 2.2 | 17 |
| 51 | Implications of a New Radiological Approach for the Assessment of Paget Disease. <i>Calcified Tissue International</i> , 2012, 91, 409-415. | 3.1 | 15 |
| 52 | Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. <i>BMJ Open</i> , 2019, 9, e030689. | 1.9 | 15 |
| 53 | Primary biliary cholangitis and bone disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 63-70. | 2.4 | 13 |
| 54 | Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis. <i>Liver International</i> , 2020, 40, 2767-2775. | 3.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Characteristics of Early Paget's Disease in <i>SQSTM1</i> Mutation Carriers: Baseline Analysis of the ZIPP Study Cohort. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1246-1252. | 2.8 | 12 |
| 56 | Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study. <i>Osteoporosis International</i> , 2021, 32, 1333-1342. | 3.1 | 12 |
| 57 | Balancing benefits and risks in the era of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1988397. | 2.7 | 10 |
| 58 | Concordance between direct and indirect measurements of free 25-OH vitamin D. <i>Clinica Chimica Acta</i> , 2017, 475, 169-171. | 1.1 | 9 |
| 59 | Uncommon local reaction at the injection site of subcutaneous methotrexate. <i>Rheumatology</i> , 2018, 57, 27-27. | 1.9 | 9 |
| 60 | Bisphosphonates in inflammatory rheumatic diseases. <i>Bone</i> , 2021, 146, 115887. | 2.9 | 9 |
| 61 | Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases. <i>Bone</i> , 2022, 162, 116483. | 2.9 | 8 |
| 62 | Bone Turnover Markers: A Clinical Review. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2015, 13, 83-97. | 0.8 | 6 |
| 63 | Identificaci3n de hipofosfatasa en la pr3ctica cl3nica: manifestaciones cl3nicas y recomendaciones diagn3sticas en pacientes adultos. <i>Medicina Cl3nica</i> , 2018, 150, 75-79. | 0.6 | 6 |
| 64 | Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone. <i>Bone</i> , 2019, 124, 132-136. | 2.9 | 5 |
| 65 | Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355. | 3.8 | 5 |
| 66 | Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy. <i>Journal of Bone and Mineral Metabolism</i> , 2002, 20, 116-120. | 2.7 | 4 |
| 67 | Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1774-1782. | 2.8 | 3 |
| 68 | Significado cl3nico del aumento de los valores s3ricos de FGF-23 en la displasia fibrosa. <i>Medicina Cl3nica</i> , 2018, 151, 65-67. | 0.6 | 2 |
| 69 | Response Letter to the Editor "Diamond et al, <i>JBMR</i>. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1185-1186. | 2.8 | 2 |
| 70 | FRI0487...UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , . | | 2 |
| 71 | Imaging Follow-up of SAPHO Syndrome Treated With Zoledronic Acid. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e155-e157. | 0.9 | 2 |
| 72 | Inflammatory arthropathy of the manubriosternal joint. <i>Rheumatology</i> , 2014, 53, 1731-1731. | 1.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Invasive Mycobacterium marinum infection. Joint Bone Spine, 2015, 82, 462. | 1.6 | 1 |
| 74 | Identification of hypophosphatasia in a clinical setting: Clinical manifestations and diagnostic recommendations in adult patients. Medicina Clínica (English Edition), 2018, 150, 75-79. | 0.2 | 1 |
| 75 | Fusion of sacroiliac joints in acromegaly: a challenging finding. Rheumatology, 2020, 59, 898-898. | 1.9 | 1 |
| 76 | RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , . | | 0 |
| 77 | Response to: Some Questions About the Article "The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report". Journal of Bone and Mineral Research, 2020, 35, 212-213. | 2.8 | 0 |
| 78 | Bone Disease in Patients with Cirrhosis. , 2015, , 295-305. | | 0 |
| 79 | Posicionamiento de la Sociedad Española de Reumatología (SER) y la Sociedad Española de Investigación y Metabolismo Mineral (SEIOMM) respecto a romosozumab. Reumatología Clínica, 2021, , . | 0.5 | 0 |
| 80 | Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab. Reumatología Clínica (English Edition), 2022, , . | 0.3 | 0 |